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ABSTRACT
Pharmacologic Immunomodulation of Macrophage Activation by Caffeine
Ryan Perry Steck
Department of Microbiology and Molecular Biology, BYU
Master of Science
Caffeine is one of the most widely used neurostimulants in the world and there is
considerable debate on its effect in immune cells. One of its main targets is proposed to be
adenosine receptors which mediate an anti-inflammatory switch in activated immune cells while
another target is phosphodiesterase where it acts as an inhibitor. In macrophages, caffeine has
been shown to cause both pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes. If the
primary effect of caffeine on macrophages were to antagonize adenosine receptors we would
expect cells exposed to caffeine to have a prolonged M1 response. However, we show that
caffeine suppresses phagocytosis at physiological concentrations (an indicator of M2 phenotype).
This suppression was reversed when macrophages were pretreated with protein kinase A
inhibitor, suggesting that at physiological concentrations caffeine’s phagocytic suppression may
be due to its function as a phosphodiesterase inhibitor, pushing cells towards an M2 fate.
However, mRNA expression profiling suggests that caffeine can modulate A2A receptor
expression and suppress MKP-1 expression, a hallmark of M1 macrophages.
Caffeine is, therefore an immunomodulator that can suppress or prolong inflammatory
responses in macrophages, which may account for the abundance of contradicting evidence in
the literature. Additionally, these effects are complicated by regular caffeine intake and fitness
level, emphasizing that tolerance and immune robustness are important factors in macrophage
activation.
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INTRODUCTION
Macrophages
Macrophages are mononuclear immune cells derived from monocytes from the myeloid
lineage which respond to stimuli and differentiate into immune effector cells. They perform a
variety of functions ranging from the phagocytosis of debris and foreign particles to the repair
and remodeling of damaged tissues.11 Different subspecialties of macrophages exist in locations
throughout the body:
osteoclasts in the bone
secrete massive
amounts of acid and
proteinases to degrade
the matrix to release
calcium ions when the
blood calcium levels
are low,8 bone marrowderived macrophages
Figure 1 Hematopoietic lineage of monocytes, macrophages, and dendritic cells12

promote retention of

hematopoietic stem cells and progenitor cells,12 and lymph node subcapsular sinus macrophages
neutralize invasion threats to the central nervous system (CNS) by neurotropic viruses.31
Alveolar macrophages trap and eliminate debris in the lungs, and Kupffer cells in the liver help
recycle red blood cells.6 Microglial cells in the brain scavenge the CNS for infectious agents or
damaged neurons to protect against disease. All of these subtypes are part of the mononuclear
phagocyte system that helps maintain homeostasis in the body.
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Macrophages express a variety of cellular markers including: CD14, CD40, CD64, F4/80
(mice)/EMR1 (human), lysozyme M, MAC-1/MAC-3, and CD68.34 The most commonly used
markers in biological assays are CD16 and CD14. CD16 is a low affinity Fc receptor that is
expressed on natural killer cells, neutrophils, and monocytes. It binds the Fc portion of
antibodies and activates antibody-dependent cell-mediated cytotoxicity.33 CD14 is a co-receptor
for toll-like receptor 4 (TLR-4) and binds lipopolysaccharide (LPS) with the help of LPSbinding protein (LBP). CD14 is expressed almost solely on macrophages, but is also found at a
much lower concentration on neutrophils. The soluble form of the receptor is secreted in the liver
and may confer LPS responsiveness to CD14- cells.21 When LPS binds the CD14/TLR4
complex, MyD88 and TIRAP are recruited. This attracts IRAK1/4 and activates TRAF6, leading
to the activation of IKK and MAPK. IKK then phosphorylates and degrades I-țB, leading to
nuclear translocation of the transcription factor NF-țB. NF-țB activates pro-inflammatory
pathways resulting in an pro-inflammatory response (Figure 2).15
Macrophage Functions
Traditionally, macrophages have been seen only as immune cells, and their homeostatic
responsibilities have been overlooked. Mosser et al, proposed that macrophages exist in three
main categories: host defense, wound healing, and immune regulation.47 These categories can
mix to create different subcategories of cells, which results in the variety of macrophage
functions we see in vivo. The janitorial aspect of a macrophage’s job may include clearing
extracellular debris or recycling apoptotic cells. Often there is a danger signal in the debris that
can activate macrophage’s immune regulatory functions.
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Figure 2 LPS stimulates MyD88 signaling15

When a danger signal is recognized, one of the first cellular responders are the tissue
resident macrophages. Molecular signals from the pathogen called pathogen associated
molecular patterns (PAMPs) are recognized by pattern recognition receptors (PRRs). One
important class of PRRs is the toll-like receptor which, upon interaction with PAMPs, induces
3

NF-ț% expression and MAPK pathway signaling. This signaling cascade stimulates the
production and secretion of pro-inflammatory mediators and the recruitment and activation of
other immune cells. Macrophages can also recognize opsonized pathogens and engulf and
degrade them in intracellular compartments through a process called phagocytosis. Although
phagocytosis has been observed since the groundbreaking studies by Metchnikoff in 1905,18
there is still much unknown about the signaling pathways involved. When a pathogen becomes
opsonized by antibody or complement proteins, macrophages can then recognize these pathogens
via the complement receptor 3 (iC3b bound antigen) or Fc receptors (IgG bound antigen). There
are three classes of Fc receptors: Fc-Ȗ, Fc-ĮDQG Fc-İThe most important class for phagocytosis
is Fc-Ȗ which contains five subtypes: FcȖ5I (CD64), FcȖ5IIA (CD32a), FcȖIIB (CD32b),
FcȖ5IIIA (CD16a), and FcȖ5IIIB (CD16b), which all differ in affinity for IgG antibody due to
structural variations. Upon binding, the receptors cluster to form lipid rafts with immunoreceptor
tyrosine-based activating motif (ITAMs) that initiate an intracellular signaling cascade resulting
in actin polymerization.9
The signaling cascade starts when (ITAM)-containing subunits are phosphorylated by
members of the Src family. The phosphorylated receptors/ITAMs become docking sites for Syk,
a tyrosine kinase. After docking, Syk activates downstream signals including
phosphatidylinositol-3-kinase (PI3K), causing generation of 3’-phosphoinositides (PI3) at the
phagosomal cup. The phagosomal cup is a cup-shaped structure, formed principally by
invagination of the plasma membrane during the early stages of phagocytic uptake of particles by
cells.40 Wiskott-Aldrich syndrome proteins (WASP’s) act as molecular scaffolds by associating
with PIP2 (a phosphoinositide) on the membrane. When WASP binds both PIP2 and the Rho
GTPase Cdc 42, it activates the actin-nucleating function of Arp2/3. 53 The Rho and Rac
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Figure 3 Fc receptor activation and signaling22
Fc receptor activation results in actin nucleation and polymerization. This is the basis of
pseudopod formation which allows phagocytes to engulf extracellular pathogens for destruction
in intracellular vesicles

GTPases are generally involved in all phagocytic activating pathways. Actin nucleation is the
basis of forming pseudopod extensions (Figure 3).
Pseudopods form by actin microfilament polymerization and assembly. These “fingerlike” projections extend, acting like probes by which they identify pathogens.20 Once around a
5

pathogen, they fuse to form an endosomal compartment called a phagosome. If the pathogen is
large, the endoplasmic reticulum can supply extra membrane to surround the object, possibly
contributing to slower phagocytic rates (Figure 4).1, 17 Beningo et al. recently revealed that
mechanical properties of the target may also affect phagocytic rates, with macrophages favoring
more rigid objects.5 They also observed that engulfment of soft particles can be increased by
activating Rac1and lysophophatidic acid, which suggests a Rac-1 dependent mechanosensory
mechanism for phagocytosis. In our experiments we used latex microspheres engineered for low
manufacturing diversity to eliminate bias due to mechanical properties.
After engulfment, the intracellular vesicle then fuses with a lysosome to form the
phagolysosome which contains enzymes to lower the pH and degrade its contents. Among these
enzymes is NADPH oxidase which generates reactive oxygen species that can be converted into
oxidizing agents like hypochlorite that can damage pathogens. Degraded components of the
vesicles are loaded onto major histocompatibility complexes and presented to T cells to activate
the adaptive immune response. T cells in return secrete cytokines such as IFNȖ to activate the
macrophage. Macrophages can be further activated by their environment and by the nature of the
pathogens they ingest. The extent of macrophage activation has recently been shown to play a
major role in many diseases such as cancer, arthritis, sepsis, and autoimmune diseases.2, 48
Extensive research on the signals involved in macrophage activation has revealed that at least
two main subtypes of macrophages exist. Classically activated macrophages are stimulated by
pro-inflammatory signals, while alternatively activated macrophages are usually stimulated by
anti-inflammatory signals. These two phenotypes have also been termed M1 and M2, mirroring
the TH1 and TH2 phenotypes of T cells.45
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Figure 4 Endoplasmic reticulum supplies membrane for phagocytosis54
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M1 and M2 Phenotypes
The M1 macrophage clears tissue of cellular debris and pathogens via aggressive
phagocytosis and release of pro-inflammatory cytokines including: IL-1, IL-6, IL-12, IL-23, and
TNF-Į. They are also characterized by their ability to produce reactive oxygen and nitrogen
intermediates (ROI, RNI), and an increased expression of MHC class II for more efficient
antigen presentation (Figure 5).44
The M2 macrophage acts as a support cell by promoting the healing of damaged cells by
angiogenesis and tissue remodeling via secretion of anti-inflammatory cytokines and by

Figure 5 M1 and M2 stimulants and responses44
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decreasing phagocytic activity.44 The M2 group can be further subdivided by the mechanism of
activation: M2a, M2b, and M2c. Il-4 and IL-13 drive M2a activation and type II immune
responses, whereas TLR/IL-1R ligands activate the M2b suppression and immunoregulation.
M2c macrophages are stimulated by IL-10, resulting in tissue remodeling and matrix
deposition.42
While these two operationally useful polarities exist, it is widely believed that
macrophages exist mainly in the continuum between these two phenotypes.43 Regulation of this
continuum involves complex processes that have been extensively studied, yet still remain
relatively unclear. Recently it was shown that macrophages will respond to injury or infection by
upregulating pro-inflammatory (M1) responses, but later switch to an anti-inflammatory (M2)
response once the infection is under control.14, 46 One proposed mechanism for this switch
involves the activation of adenosine receptors in macrophages as they mature, to decrease the
initial pro-inflammatory response and promote vascularization and wound repair.14

Adenosine Receptors
Adenosine receptors (ARs) are classed into four subtypes: A1, A2A, A2B, and A3
receptors. Each receptor type has a different affinity for adenosine and different signaling
pathways, and not all cells express every subtype.27 Activating the receptors leads to inhibition
or excitation of adenylate cyclase (Figure 6-7) which can control the inflammatory response in a
number of immune cells.36 In macrophages, A2AR plays a critical role in regulating the
angiogenic switch from M1 to M2 phenotypes. During an infection, over-activation of the
inflammatory response would cause severe damage; therefore a negative regulatory system is
needed to induce a switch from a pro-inflammatory response to an anti-inflammatory response.
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Figure 6 Action of adenosine in immune cells19, 36
(Top) Adenosine binds adenosine receptors which can excite or inhibit adenylate cyclase, thus
increasing or decreasing concentrations of cAMP. cAMP levels can target kinase proteins like
p38 MAPK (bottom) that can then release pro-inflammatory cytokines in macrophages.
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Adenosine release has been proposed as one of these negative feedback systems. Macrophages
initiate inflammation through TLR-dependent activation to an M1 phenotype, but are then
switched into an angiogenic phenotype by adenosine generated in response to hypoxia/ischemia
within the wound area.50
This is accomplished when initial activation of macrophages by TLR agonists markedly
induce expression of A2AR and A2BR, essentially priming these macrophages to respond to
increased local levels of extracellular adenosine and suppressing the pro-inflammatory
response.10 Activation of A2AR by adenosine inhibits phagocytosis and inflammatory cytokine
production, and increases IL-10 and pro-angiogenic factor production (Table 1). Antagonists of
A1R and A2AR were recently discovered to have the ability to induce a pro-inflammatory or antiinflammatory phenotype in microglial cells26. Additionally, it was shown that blockade of A2BR
in mice enhances macrophage-mediated clearing of bacteria and increases TNF-Įand IL-6
production.4, 14 Analogs of adenosine and antagonists of its receptors are therefore of interest as
therapeutics to regulate inflammation.
Table 1 Expression of adenosine receptors by subtype 25

M1 and M2 macrophages both express A2A receptors which have similar functions. In M1 macrophages A2A receptor
signaling inhibits phagocytosis and increases IL-10 production, whereas A2A receptor signaling in M2 macrophages
functions to perpetuate M2 activity.
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Adenosine receptors and MAPK/MKP-1
Adenosine has also been shown to affect the mitogen-activated protein kinase (MAPK) pathway
of inflammation. Knockout of A2AR results in prolonged mitogen-activated protein kinase
(MAPK) phosphorylation, leading to increased activation of pro-inflammatory pathways.61

Figure 8 The transition from pro-inflammatory to anti-inflammatory state in tissue repair52.
MAPK and MKP-1 regulate the angiogenic switch. Knockdown of A2AR prolongs p38 MAPK
phosphorylation, suggesting that adenosine signals through MPK-1 to activate an anti-inflammatory phenotype.

During wound repair in muscle cells, MAPK dephosphorylation by MAP kinase phosphatase-1
(MKP-1) induces an anti-inflammatory response (Figure 8). However, MKP-1 activation is
delayed until approximately three days post infection.52 It is possible that adenosine receptor
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signaling activates MKP-1 activity, and that the prolonged MAPK phosphorylation in A2AR
knockouts is due to lack of active MKP-1. We extended the observation window in our
experiments to three days in order to study the effect of caffeine on MKP-1 activation.

Adenosine Receptors and Cancer
Extracellular adenosine accumulates in the tumor microenvironment due to hypoxia and
inflammatory conditions. This accumulation may be inhibiting the cytotoxic capacity of immune
cells,38, 39, 49, 57 a phenomenon known as the Hellstrom paradox.28 Hellstrom et al. noted that
despite tumors being recognized by the immune system and generating anti-tumor T cells, the
tumors still persist. Similar studies have shown that macrophages surround breast tumors, but are
incapable of producing a cytotoxic response and instead promote angiogenesis and
vascularization of tumor tissue.7 Accumulation of adenosine in the tumor microenvironment may
be contributing to this phenomenon. The source of excessive adenosine was, until recently,
unknown. Wang et al. recently demonstrated that CD73, a hallmark of many cancers, acts at
receptors A2AR and A2BR, causing immunosuppression in the tumor microenvironment.63 CD73,
also known as ecto-5’-nucleotidase, is a membrane bound enzyme that catalyzes the conversion
of purine mononucleotides to nucleosides, its main substrate being AMP. Adenosine generated
by this enzyme acts by binding to adenosine receptors on surrounding cells resulting in tumor
promotion.62 Blockade of A2AR/A2BR in mouse macrophages with CD73+ tumors significantly
decreased tumor growth and metastasis.3 Knockdown of ARs in the tumor microenvironment
decreases VEGF levels and angiogenesis in lung carcinoma, suggesting that adenosine signaling
may be responsible for propagation of tumor growth factor signaling.56 Therefore, antagonism
of AR signaling by caffeine or its analogs may be of interest as a therapeutic in cancer.
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Caffeine
Caffeine is the most widely used neuroactive compound worldwide.24 It is an analog of
adenine a member of the xanthine family of compounds. It is metabolized by cytochrome P450
oxidase into three metabolites also in the xanthine family: theophylline (4%), theobromine
(12%), and paraxanthine (84%) (Figure 9). Theophylline and paraxanthine have neurotropic and

Figure 9 Caffeine and its metabolites.
Left, caffeine is metabolized into three metabolites by cytochrome P450 oxidase. Right, caffeine is an analog
of adenine and may function as an antagonist at adenosine receptors. (Public Domain)

immunomodulatory activity similar to caffeine.30, 58
Caffeine’s mechanism of action in immune cells has been an issue of debate for some
time. Part of this debate is the result of a number of studies using supraphysiological
concentrations, which are often rightfully disregarded. Some studies suggest that the upper limit
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for caffeine concentration in serum is 75 M.16 Others suggest that this is an order of magnitude
too low because of the low bioavailability of some forms of caffeine.29, 55 Still, some researchers
have argued that because its metabolites have identical bioactivity, the effective concentration of
caffeine is much higher than both of these estimates.32 For example, Van Furth et al. showed
that theophylline, theobromine, paraxanthine and caffeine all have a suppressive effect on TNF-Į
production in human leukocytes.60 In our experiments we used a range of concentrations in order
to observe the immunological effect of caffeine at physiological as well as supraphysiological
concentrations. The mechanism of action of these methylxanthines has been a subject of study
for many years, yet still remains somewhat unclear.
There is a significant body of evidence to suggest that many of the physiological effects
of dietary caffeine are mediated by antagonism of ARs.41 Caffeine binds non-selectively to ARs
with a Ki of 50-55 M for A1 and A2 receptors. Binding of caffeine prevents the activation of
ARs by adenosine. The activation of ARs on immune cells generally leads to the suppression of
pro-inflammatory cytokines.50 This suppression of cytokine production has been observed
following stimulation with agonists of adenosine A1, A2, and A3 receptors, as well as adenosine
itself.35, 37 Therefore if the primary effect of caffeine in macrophages was to antagonize ARs, we
would expect caffeine to prolong pro-inflammatory responses. However, caffeine suppresses
pro-inflammatory cytokine production in whole-blood macrophages.30 Caffeine is also a
phosphodiesterase inhibitor, increasing cAMP levels in cells and thus increasing activation of
downstream targets like phosphokinase A (PKA). PKA belongs to a family of kinases that have
two regulatory subunits controlled by cAMP binding (Figure 10). When cAMP levels are high,
two cAMP molecules bind the regulatory subunits thus removing them from the active site
allowing the catalytic subunits to interact with protein kinases to phosphorylate Ser or Thr
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residues. The increased activation of PKA may be responsible for suppression of proinflammatory cytokine production in macrophages.30

Figure 10 The phosphodiesterase inhibitor activity of caffeine51

G-proteins (adenosine receptors) activate adenylate cyclase, generating cAMP. Caffeine inhibits cAMP
phoshodiesterase (cAMP PDE) leaving high levels of cAMP in the cell which is free to activate PKA phenotype.

Project Overview
In order to investigate this suppressive effect of caffeine, we studied the inflammatory
profile of macrophages after exposure to caffeine and PKA inhibitor. Using a phagocytic assay
and gene expression assays, we sought to elucidate caffeine’s mechanism of action at a range of
concentrations and time points. We hypothesized that caffeine would suppress phagocytosis at
physiological concentrations and that this suppression is due to increased activation of PKA by
accumulation of intracellular cAMP; thus the PKA inhibitor would negate the effects of caffeine.
16

We also hypothesized that at higher concentrations, caffeine will antagonize adenosine receptors
and reverse phagocytic suppression due to PKA activation. We further hypothesized that
adenosine receptor expression would increase with macrophage aging and that this increase in
expression would contribute to the effects on phagocytosis.

MATERIALS AND METHODS

Tissue culture
Blood was drawn intravenously from 11 volunteers ages 20-30, and information was
recorded on age, gender, caffeine intake, and exercise level (BYU IRB # X 14194). Patients who
regularly consumed 400 mg/wk were considered regular caffeine users. Patients who exercised
for 30 mins, more than twice a week, were considered regular exercisers.
Leukocytes were separated from whole blood using lymphocyte separation medium
(STEMCELL Tech), then washed and resuspended in RPMI 1640 medium supplemented with
20% human serum from the blood donor. Cells were then seeded in 12-well plates at a
concentration of 106 cells/mL and incubated (37°C, 5% CO2) for 1h - 3 d. Adherent cells are
widely accepted to be differentiated macrophages.64 Cells collected after 1 h were termed “Day
0” and used as a baseline control for phagocytosis and adenosine receptor expression. Remaining
cells were allowed to culture for 1 d or 3 d after isolation with or without PKA inhibitor (Rp-8Br-cAMPS, Santa Cruz Biotech), final concentration 10-5M for 0.5 h. Then caffeinesupplemented media (Sigma, CAS # C8960) was added, final concentration 35 M-15 mM, for 2
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h followed by LPS stimulation (1g/mL) and further incubation (37°C, 5% CO2) for 22 h. Cell
viability was accounted for and no difference was seen between days.
Caffeine Concentration
Caffeine concentration was measured before and after cell culture to ensure uniform
concentration across the 24 h incubation period. Caffeine’s absorbance was read at 300 nm using
a Synergy HT Multi-Mode Microplate reader (BioTek) at time zero, 2 h, and 24 h post
incubation.
Phagocytosis Assay
After 24 h incubation with caffeine, 2 m phycoerythrin (PE)-conjugated polychromatic
red latex microspheres, or beads, (Polysciences, Inc.) were added to wells (~109 particles/mL)
and allowed to incubate for 1 h. This concentration was chosen to ensure the beads were not a
limiting factor in phagocytosis rates. The beads were suspended in fetal bovine serum (FBS) to
allow proper phagocytosis by macrophages and to prevent beads from sticking to the cell
membranes (Figure 11).

Figure 11 Fluorescent microscopy

(Left) beads without FBS; (Right) beads suspended in FBS, demonstrating how FBS
prevents clumping and sticking of beads to cells.
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Flow Cytometry Analysis
After 1 h, cells were placed on ice to stop phagocytosis and macrophages were isolated
by their adherence to the plate. Macrophages were collected using a cell scraper, washed twice
and stained with human CD14-APC/Cy7 antibody (BioLegend) for macrophage definition. After
washing, samples were analyzed using a BD Accuri C6 flow cytometer and software. FL4-A
represents CD14+ events and FL2-A represents PE+ events (Figure 12B,C). Macrophage
phagocytosis was stratified by gating on PE+ peaks representing 1, 2, and 3+ beads (Figure 12A).
The “2 bead” and “3+ bead” populations are used in analysis of phagocytic aggressiveness and
are used to calculate the percentage of cells that are “highly aggressive.” This percentage was
compared to all CD14+ events to measure macrophage activation.

B

A

C

3+ bead
2+ bead
1+ bead

Figure 12 Flow cytometry analysis on BD Accuri software.

A) FL4-A represents CD14+ events, FL2-A represents PE+ events. Distinct populations of cells engulfing 1, 2, and
3+ beads can be seen ascending in PEfluorescence. B) CD14+ events are separated to show cells that are engulfing 1
bead (green), 2 beads (blue), and 3+ beads (pink). C) PE+ events overlayed with CD14+ in red. The 1 bead
population shows slight contamination with non-CD14+ events (black). This may be residual B cells which might
have beads attached on the membrane. The 1 bead population was not used in analysis because of this
contamination.
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RT-qPCR
Macrophages were prepared in the same manner as for the phagocytosis assay. At the end
of the 24 h incubation with caffeine, macrophages were isolated by their adherence and collected
for lysis. RNA from lysates was isolated using RNAqueous kit (Ambion) and analyzed in our
StepOne Real Time PCR System using qScript™ One-Step qRT-PCR Kit (Quanta Biosciences)
and Taqman Gene Expression Assays (Life Technologies). ActinB was used as an endogenous
control revealing the mRNA expression levels of adenosine receptor A2A, and MAP kinase
phosphatase (MKP-1).

Statistical Analysis
Results from gene expression analysis were analyzed using StepOne software,
determining the fold change using the equation: fold change = 2-ǻǻ&T. Treatments for both gene
expression assays and phagocytosis assays were analyzed and compared to controls using a beta
regression controlling for factors of age, gender, caffeine intake, and exercise. Matched pair ttests were used to further analyze the effect of each factor on macrophage aggressiveness.

RESULTS AND DISCUSSION

Caffeine Concentration
To ensure that caffeine concentrations remained uniform in culture throughout the
experiment, caffeine’s absorbance was read at 0 h, 2 h, and 24 h post-incubation. No significant
difference was seen in caffeine concentration after incubation (Figure 13).
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Figure 13 Caffeine concentration by absorbance.

Media from cell culture was sampled and measured using spectrophotometry to identify concentration of caffeine.
Wavelength = 300 nm. All other variable besides caffeine concentration were kept constant. No significant differences
were seen between time points, suggesting that caffeine concentrations remained relatively stable throughout the 24 h
incubation.

P-value
* <.05
**<.01

Figure 14 Macrophage exhaustion over three days without caffeine treatment.

Macrophage aggressiveness as measured by percent highly aggressively engulfing. Over three days,
macrophage aggressiveness decreases significantly by 34.4% (p-value = 0.0003 , compared to control day
0. Data was generated using a paired t-test. n=11
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Macrophage Exhaustion
In order to observe the phagocytic activity of macrophages as they mature, exhaustion
was measured over three days using phagocytosis as an indicator of aggressiveness. Figure 14
shows that in non-caffeine-treated (control) macrophages, cell maturity reduced phagocytosis
after three days. On day three total phagocytosis was reduced by 34.4% (p-value = 0.0003, 95%
CI [13.8%, 37.6%]). This reduction confirms previous work showing that under homeostatic
conditions macrophages shift to an M2 phenotype.46

Caffeine and Phagocytosis
Caffeine-treated macrophages were analyzed for aggressiveness based on the patient’s
caffeine intake, gender, age, and exercise level. PKA inhibitor was also added to determine
caffeine’s mechanism of action. A beta regression accounting for the overall effect of patient
factors was performed (Figure 15). Caffeine’s effect becomes more significant with cell
maturity, with day three having the most profound effect. Pre-treatment with PKA inhibitor
negates the effect of caffeine. This suggests that the effect on aggressiveness seen in caffeinetreated macrophages is due to the phosphodiesterase inhibitory activity of caffeine. Beta
regression revealed that patient caffeine intake and regular exercise have a significant effect on
macrophage response to caffeine treatment, while other factors had no significant effect or
interaction.
Following the beta regression results, further analysis using a matched pair t-test was
done to reveal the effect of patient caffeine intake and exercise for each day. Day 0 results
showed no significant difference regardless of caffeine treatment, caffeine intake, or exercise
level (data not shown).
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P-value
* <.05
**<.01

Figure 15 Beta regression on macrophage aggressiveness accounting for all patient variables

Beta regression accounting for gender, age, caffeine intake, and regular exercise was
performed for each day of analysis. Bars represent the average beta regression value of
aggressiveness. Day 0 (gray) showed no significant difference in any treatments with no factor
having a significant effect. Day 1 (blue) showed a significant decrease in aggressiveness after
100 M caffeine treatment (p-value = 0.0428), but addition of PKA inhibitor reversed this
effect (p-value = 0.496). Day 3 (green) showed significant decreases in aggressiveness when
treated with both 100 M caffeine (p-value = 0.012) and 750 M caffeine (p-value
= 0.019). Addition of PKA inhibitor reversed this suppression in both concentrations (p-value
= 0.92 and 0.509, respectively). n=11
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Figure 16 shows the effect of caffeine treatment on non-caffeine drinkers’ macrophages
on day 1. Macrophages treated with 100 M and 750 M caffeine showed a 23.5% and 11.7%
reduction in aggressiveness, respectively (p-value = 0.0480 and 0.0116, respectively). However,
macrophages treated with 100 M or 750 M caffeine and PKA inhibitor (+pka_inh) showed no
significant decrease in aggressiveness (p-value = 0.8773 and 0.8177, respectively).

P-value
* <.05
**<.01

Figure 16 Caffeine’s effect on day 1, non-caffeine drinkers.

Caffeine reduces macrophage aggressiveness in non-caffeine drinkers at 100 M (p-value = 0.0480)
and 750 M (p-value = 0.0116). Differences report was generated using a matched pairs t-test. n=6
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Figure 17 shows the effect of caffeine treatment on caffeine drinkers’ macrophages on
day 1. A significant difference in aggressiveness is seen in the non-caffeine-treated cells between
the “-caff +pka_inh” and the “-caff” control. This may be due to residual caffeine in the serum of
these patients.

P-value
* <.05
**<.01

Figure 17 Caffeine’s effect on day 1 in regular caffeine drinkers

With caffeine drinkers’ macrophages, there was no significant difference in macrophage aggressiveness in any
concentration or with PKA inhibitor except a small difference between the control and control + PKA inhibitor
(p-value = 0.0439). This could be due to the inhibition of caffeine already in the serum of these patients. Data
generated using a matched pair t-test. n=5
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Figure 18 shows the effect of caffeine treatment on non-caffeine drinkers’ macrophage
aggressiveness after day 3 of incubation. Addition of 100 M caffeine resulted in a 25.4%
reduction in aggressiveness (p-value = 0.0314). Addition of 750 M caffeine reduced
aggressiveness by 36.9% (p-value = 0.0037). PKA inhibitor prevented the reduction caused by
100 M caffeine (p-value = 0.2147), but was unable to completely reverse the effect of 750 M
caffeine, which still had a 21.9% decrease in aggressiveness compared to controls (p-value =
0.0117).

P-value
* <.05
**<.01

Figure 18 Caffeine’s effect on day 3, non-caffeine drinkers

Non-caffeine drinkers’ macrophages show significant reductions in aggressiveness when treated with either
100 M (p-value = 0.0314) or 750 M caffeine (p-value = 0.0037). Addition of PKA inhibitor reversed
this reduction for 100 M caffeine, but not totally for 750 M caffeine (p-value = 0.0117). Data generated
using a matched pairs t-test. n=6
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Figure 19 shows caffeine drinkers’ macrophage aggressiveness 3 d post stimulation and
after caffeine treatment. No significant difference was seen in any treatment group. This
confirms a form of caffeine tolerance that has been shown to exist in chronic caffeine drinkers.13

Figure 19 Caffeine’s effect on day 3, caffeine drinkers

Caffeine drinkers’ macrophages show no sensitivity to caffeine at 100 M or 750 M concentrations. PKA
inhibitor also had no effect on these cells’ aggressiveness. Data generated using a matched pair t-test. n=5
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Exercise and Caffeine Suppression
Figure 20 and 21 show the effect of caffeine on macrophages in exercising versus nonexercising patients. There was no difference in macrophage aggressiveness between exercising
and non-exercising patients. However, in non-exercising patients, macrophage aggressiveness
significantly decreased after treatment with 100 M and 750 M caffeine by 23.8% (p-value =
0.0265) and 24.7% (p-value = 0.0215), respectively, and PKA inhibitor prevented this effect (pvalue = 0.8687, and 0.2796, respectively). Caffeine intake was not suspected to be a confounding
variable since both regular exercisers and non-exercisers both had an equal ratio of caffeine/noncaffeine drinkers and beta regression revealed no significant interaction. This finding adds
confidence to recent suspicions that regular exercise may boost immune robustness and protect
against immunosuppression by modulators such as caffeine.59

Figure 20 Effect of exercise on aggressiveness.

0= no regular exercise, 1= regular exercise. A studnent’s t-test revealed no effect on overall
aggressiveness was observed in exercising versus non-exercising patients (p-value = 0.5997).
n=5(non -xerciser) and n=6(exerciser)
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P-value
* <.05
**<.01

A
Regular exercisers
B
Non-exercisers

P-value
* <.05
**<.01

Figure 21 Effect of regular exercise on response to caffeine treatment

A) Caffeine has a significant effect on non-exercisers (p-value = 0.0207 at 100 M, p-value = 0.0394 at 750
M) and PKA inhibitor reversed the effect. However, in regular exercisers (B) caffeine had no significant
effect. Data was combined across all days post stimulation to see an overall effect. Differences report
generated using a matched pair t-test.
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Adenosine Receptor Exhaustion
Adenosine receptor A2A mRNA expression was measured in macrophages from three
patients- one of which had recent caffeine intake- using an RT-qPCR gene expression assay.
A2AR expression increased over three days by 2.29 fold/day (p-value <.0001) (Figure 22). The
patient’s caffeine intake had no effect. Addition of PKA inhibitor also had no effect on
expression. Addition of PKA inhibitor was not further considered in analysis because of the lack
of effect.

Chronic caffeine intake
Chronic caffeine intake + PKA inhibitor

Figure 22 Adenosine receptor A2A expression over three days without caffeine.

Adenosine receptor expression increases by 2.287 fold/day (p-value <.0001). Cells were not treated with caffeine, but were
treated with PKA inhibitor. The inhibitor had no effect of adenosine receptor expression. Caffeine intake also had no
significant effect on expression. n=3

Caffeine and Adenosine Receptor Expression
Caffeine treatment reduced A2AR expression on day three. 100 M caffeine reduced
A2AR expression by 7.6244 fold (p-value <.0001) and 750 M caffeine reduced it by 8.1194 fold
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(p-value <.0001). Addition of PKA inhibitor did not restore expression to normal levels (p-value
= 0.0057 for 100 M caffeine, p-value = 0.0327 for 750 M caffeine).

Day 3

Figure 23 Adenosine A2A receptor expression after caffeine treatment.

Adora2a expression in human macrophages over three days after 24 h treatment with 100M caffeine
(+caff_100uM), 750 M caffeine (+caff_750uM). Caffeine control groups showed an increase in adenosine receptor
expression whereas cells treated with 100 M caffeine decreased on by 7.62 fold on day three. Cells treated with
750 M caffeine decreased by 8.12 fold on day three. PKA inhibitor had no effect on expression. n=3
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The reduction in expression in caffeine treated macrophages may be due to a negative
feedback mechanism initiated by the blockade of A2AR signaling by caffeine. PKA inhibitor’s
failure to restore expression to normal levels suggests that decreased A2AR expression is not a
downstream effect of phosphodiesterase inhibitor activity, but that caffeine is most likely binding
antagonistically to adenosine receptors at physiological concentrations. The delay of this
suppression until day three correlates with our work and work previously done showing that
adenosine receptor expression increases with age.23 Since signaling through adenosine receptors
initiates an anti-inflammatory response, an increase in receptor expression would provide a
default feedback mechanism to prevent tissue damage from prolonged exposure to proinflammatory attack.

MKP-1 Expression
MKP-1 mRNA expression was measured with the same protocol as A2AR mRNA
expression as described above. PKA inhibitor had no effect on expression again and was
excluded from further analysis for simplicity. Expression was significantly affected by chronic
caffeine intake (p-value = 0.039). Chronic caffeine intake in one patient coupled with treatment
of 750 M caffeine resulted in up-regulation of MKP-1 on day three (Figure 24). This may be
due to caffeine hyposensitivity in that patient, resulting in an increased stimulation of adenosine
receptors and subsequently an increased activation of MKP-1. Excluding this, caffeine treatment
reduced MKP-1 expression on days 1 and 3. This, along with a decreased A2AR expression
profile, provides convincing evidence that caffeine is causing a prolonged inflammatory
response. This would account for the prolonged MAPK phosphorylation seen by Wang et al.61
However, this contradicts our phagocytosis data. We conclude that caffeine has both an anti-
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inflammatory and a pro-inflammatory effect on immune cells. These effects may present as a
phenotypically distinct macrophage exhibiting both pro- and anti-inflammatory characteristics.
Such a phenomenon would fit the abundant, contradictory in-vivo and epidemiological evidence
available on caffeine. Further study on the binding constants and IC50 value of caffeine in vivo
would illuminate these complicated mechanisms and help us understand the overall profile of a

No caffeine

100 M caffeine

750 M

Figure 24 MKP-1 expression after caffeine treatment.

MKP-1 expression in human macrophages over three days after 24 hour treatment with no caffeine (black)
100M caffeine (blue), or 750 M caffeine (green). 24 h treatment with caffeine and PKA inhibitor began 24 h
prior to the day of harvesting. Two outliers in the 750 M group are from the chronic caffeine drinker that had
had caffeine in the past 15 h. Addition of PKA had no effect on MKP-1 expression (data not shown). n=3

caffeine-treated immune system.
The regulation of macrophage activation is a complex process with many moving pieces
that interact at varying time points and concentrations. Caffeine inhibits phosphodiesterase
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causing suppressed phagocytosis, and antagonizes adenosine receptors causing pro-longed
inflammatory responses (Figure 25). Both effects seem to be complicated by regular caffeine
intake, while phagocytic suppression additionally depends on fitness level. Further study into
caffeine as a modulator of the immune system will better inform the average consumer on the
health risks and benefits of dietary consumption.

Prolonged-inflammatory

Anti-inflammatory

CAFFEINE

A2AR
Adenylate
cyclase
phosphodiesterase

cAMP

MKP-1
PKA

IMMUNE SUPPRESSION
Figure 25 Caffeine’s proposed anti-inflammatory and prolonged-inflammatory effects.
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